APO Research
Talk to an analyst

APO RESEARCH · REPORT

Female Sexual Dysfunction Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Female Sexual Dysfunction Treatment Market Outlook and Growth Opportunities 2026

22 December 2025195 pages

Choose your research edition.

Industry ResearchFemale Sexual Dysfunction Treatment Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Female Sexual Dysfunction Treatment Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Female Sexual Dysfunction Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Female Sexual Dysfunction Treatment Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Female Sexual Dysfunction Treatment Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Female Sexual Dysfunction Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Female Sexual Dysfunction Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Female Sexual Dysfunction Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Female Sexual Dysfunction Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Female Sexual Dysfunction Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Female Sexual Dysfunction Treatment market include Novo Nordisk AS, Sprout Pharmaceuticals Inc., Emotional Brain BV, Duchesnay Inc. and AMAG Pharmaceuticals Inc., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Female Sexual Dysfunction Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Female Sexual Dysfunction Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Female Sexual Dysfunction Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Female Sexual Dysfunction Treatment market.

Female Sexual Dysfunction Treatment Segment by Company

Novo Nordisk AS

Sprout Pharmaceuticals Inc.

Emotional Brain BV

Duchesnay Inc.

AMAG Pharmaceuticals Inc.

Female Sexual Dysfunction Treatment Segment by Type

Non-hormonal Therapy

Hormonal Therapy

Female Sexual Dysfunction Treatment Segment by Application

Pelvic Floor Dysfunction

Post-orgasmic Diseases

Orgasm Disorders

Sexual Arousal Disorders

Sexual Pain Disorders

Sexual Desire Disorders

Other

Female Sexual Dysfunction Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Female Sexual Dysfunction Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Female Sexual Dysfunction Treatment key companies, revenue, market share, and recent developments.

3. To split the Female Sexual Dysfunction Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Female Sexual Dysfunction Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Female Sexual Dysfunction Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Female Sexual Dysfunction Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Female Sexual Dysfunction Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Female Sexual Dysfunction Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Female Sexual Dysfunction Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Female Sexual Dysfunction Treatment industry.

Chapter 3: Detailed analysis of Female Sexual Dysfunction Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Female Sexual Dysfunction Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Female Sexual Dysfunction Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Female Sexual Dysfunction Treatment Industry Trends Table 2. Female Sexual Dysfunction Treatment Industry Drivers Table 3. Female Sexual Dysfunction Treatment Industry Opportunities and Challenges Table 4. Female Sexual Dysfunction Treatment Industry Restraints Table 5. Global Female Sexual Dysfunction Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Female Sexual Dysfunction Treatment Revenue Share by Company (2021-2026) Table 7. Global Female Sexual Dysfunction Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Female Sexual Dysfunction Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Female Sexual Dysfunction Treatment Company, Product Type & Application Table 10. Global Female Sexual Dysfunction Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Female Sexual Dysfunction Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Non-hormonal Therapy Table 15. Significant Companies of Hormonal Therapy Table 16. Global Female Sexual Dysfunction Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Female Sexual Dysfunction Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Female Sexual Dysfunction Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Female Sexual Dysfunction Treatment Sales Value Share by Type (2021-2026) Table 20. Global Female Sexual Dysfunction Treatment Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Pelvic Floor Dysfunction Table 22. Significant Companies of Post-orgasmic Diseases Table 23. Significant Companies of Orgasm Disorders Table 24. Significant Companies of Sexual Arousal Disorders Table 25. Significant Companies of Sexual Pain Disorders Table 26. Significant Companies of Sexual Desire Disorders Table 27. Significant Companies of Other Table 28. Global Female Sexual Dysfunction Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Female Sexual Dysfunction Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Female Sexual Dysfunction Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Female Sexual Dysfunction Treatment Sales Value Share by Application (2021-2026) Table 32. Global Female Sexual Dysfunction Treatment Sales Value Share by Application (2027-2032) Table 33. Global Female Sexual Dysfunction Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Female Sexual Dysfunction Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Female Sexual Dysfunction Treatment Sales Value Share by Region (2021-2026) Table 36. Global Female Sexual Dysfunction Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Female Sexual Dysfunction Treatment Sales Value Share by Region (2027-2032) Table 38. Global Female Sexual Dysfunction Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Female Sexual Dysfunction Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Female Sexual Dysfunction Treatment Sales Value Market Share by Country (2021-2026) Table 41. Global Female Sexual Dysfunction Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Female Sexual Dysfunction Treatment Sales Value Market Share by Country (2027-2032) Table 43. Novo Nordisk AS Company Information Table 44. Novo Nordisk AS Business Overview Table 45. Novo Nordisk AS Female Sexual Dysfunction Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Novo Nordisk AS Female Sexual Dysfunction Treatment Product Portfolio Table 47. Novo Nordisk AS Recent Development Table 48. Sprout Pharmaceuticals Inc. Company Information Table 49. Sprout Pharmaceuticals Inc. Business Overview Table 50. Sprout Pharmaceuticals Inc. Female Sexual Dysfunction Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Sprout Pharmaceuticals Inc. Female Sexual Dysfunction Treatment Product Portfolio Table 52. Sprout Pharmaceuticals Inc. Recent Development Table 53. Emotional Brain BV Company Information Table 54. Emotional Brain BV Business Overview Table 55. Emotional Brain BV Female Sexual Dysfunction Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Emotional Brain BV Female Sexual Dysfunction Treatment Product Portfolio Table 57. Emotional Brain BV Recent Development Table 58. Duchesnay Inc. Company Information Table 59. Duchesnay Inc. Business Overview Table 60. Duchesnay Inc. Female Sexual Dysfunction Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Duchesnay Inc. Female Sexual Dysfunction Treatment Product Portfolio Table 62. Duchesnay Inc. Recent Development Table 63. AMAG Pharmaceuticals Inc. Company Information Table 64. AMAG Pharmaceuticals Inc. Business Overview Table 65. AMAG Pharmaceuticals Inc. Female Sexual Dysfunction Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. AMAG Pharmaceuticals Inc. Female Sexual Dysfunction Treatment Product Portfolio Table 67. AMAG Pharmaceuticals Inc. Recent Development Table 68. Research Programs/Design for This Report Table 69. Authors List of This Report Table 70. Secondary Sources Table 71. Primary Sources List of Figures Figure 1. Female Sexual Dysfunction Treatment Product Image Figure 2. Global Female Sexual Dysfunction Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Female Sexual Dysfunction Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Female Sexual Dysfunction Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Non-hormonal Therapy Image Figure 8. Hormonal Therapy Image Figure 9. Global Female Sexual Dysfunction Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Female Sexual Dysfunction Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Female Sexual Dysfunction Treatment Sales Value Share by Type (2021-2032) Figure 12. Pelvic Floor Dysfunction Image Figure 13. Post-orgasmic Diseases Image Figure 14. Orgasm Disorders Image Figure 15. Sexual Arousal Disorders Image Figure 16. Sexual Pain Disorders Image Figure 17. Sexual Desire Disorders Image Figure 18. Other Image Figure 19. Global Female Sexual Dysfunction Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Female Sexual Dysfunction Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Female Sexual Dysfunction Treatment Sales Value Share by Application (2021-2032) Figure 22. Global Female Sexual Dysfunction Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Female Sexual Dysfunction Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Female Sexual Dysfunction Treatment Sales Value (2021-2032) & (US$ Million) Figure 25. North America Female Sexual Dysfunction Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Female Sexual Dysfunction Treatment Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Female Sexual Dysfunction Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Female Sexual Dysfunction Treatment Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Female Sexual Dysfunction Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Female Sexual Dysfunction Treatment Sales Value (2021-2032) & (US$ Million) Figure 31. South America Female Sexual Dysfunction Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Female Sexual Dysfunction Treatment Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Female Sexual Dysfunction Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Non-hormonal Therapy
  • Hormonal Therapy
Applications
  • Pelvic Floor Dysfunction
  • Post-orgasmic Diseases
  • Orgasm Disorders
  • Sexual Arousal Disorders
  • Sexual Pain Disorders
  • Sexual Desire Disorders
  • Other
Companies covered
  • Novo Nordisk AS
  • Sprout Pharmaceuticals Inc.
  • Emotional Brain BV
  • Duchesnay Inc.
  • AMAG Pharmaceuticals Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Female Sexual Dysfunction Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Female Sexual Dysfunction Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Female Sexual Dysfunction Treatment Market Dynamics
  1. 2.1 Female Sexual Dysfunction Treatment Industry Trends
  2. 2.2 Female Sexual Dysfunction Treatment Industry Drivers
  3. 2.3 Female Sexual Dysfunction Treatment Industry Opportunities and Challenges
  4. 2.4 Female Sexual Dysfunction Treatment Industry Restraints
3 Female Sexual Dysfunction Treatment Market by Company
  1. 3.1 Global Female Sexual Dysfunction Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Female Sexual Dysfunction Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Female Sexual Dysfunction Treatment Company Ranking (2024-2026)
  4. 3.4 Global Female Sexual Dysfunction Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Female Sexual Dysfunction Treatment Company Product Type and Application
  6. 3.6 Global Female Sexual Dysfunction Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Female Sexual Dysfunction Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Female Sexual Dysfunction Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Female Sexual Dysfunction Treatment Market by Type
  1. 4.1 Female Sexual Dysfunction Treatment Type Introduction
  2. 4.1.1 Non-hormonal Therapy
  3. 4.1.2 Hormonal Therapy
  4. 4.2 Global Female Sexual Dysfunction Treatment Sales Value by Type
  5. 4.2.1 Global Female Sexual Dysfunction Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Female Sexual Dysfunction Treatment Sales Value by Type (2021-2032)
  7. 4.2.3 Global Female Sexual Dysfunction Treatment Sales Value Share by Type (2021-2032)
5 Female Sexual Dysfunction Treatment Market by Application
  1. 5.1 Female Sexual Dysfunction Treatment Application Introduction
  2. 5.1.1 Pelvic Floor Dysfunction
  3. 5.1.2 Post-orgasmic Diseases
  4. 5.1.3 Orgasm Disorders
  5. 5.1.4 Sexual Arousal Disorders
  6. 5.1.5 Sexual Pain Disorders
  7. 5.1.6 Sexual Desire Disorders
  8. 5.1.7 Other
  9. 5.2 Global Female Sexual Dysfunction Treatment Sales Value by Application
  10. 5.2.1 Global Female Sexual Dysfunction Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.2.2 Global Female Sexual Dysfunction Treatment Sales Value by Application (2021-2032)
  12. 5.2.3 Global Female Sexual Dysfunction Treatment Sales Value Share by Application (2021-2032)
6 Female Sexual Dysfunction Treatment Regional Value Analysis
  1. 6.1 Global Female Sexual Dysfunction Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Female Sexual Dysfunction Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Female Sexual Dysfunction Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Female Sexual Dysfunction Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Female Sexual Dysfunction Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Female Sexual Dysfunction Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Female Sexual Dysfunction Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Female Sexual Dysfunction Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Female Sexual Dysfunction Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Female Sexual Dysfunction Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Female Sexual Dysfunction Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Female Sexual Dysfunction Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Female Sexual Dysfunction Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Female Sexual Dysfunction Treatment Sales Value Share by Country, 2025 VS 2032
7 Female Sexual Dysfunction Treatment Country-level Value Analysis
  1. 7.1 Global Female Sexual Dysfunction Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Female Sexual Dysfunction Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Female Sexual Dysfunction Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Female Sexual Dysfunction Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Female Sexual Dysfunction Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Female Sexual Dysfunction Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Female Sexual Dysfunction Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novo Nordisk AS
  2. 8.1.1 Novo Nordisk AS Company Information
  3. 8.1.2 Novo Nordisk AS Business Overview
  4. 8.1.3 Novo Nordisk AS Female Sexual Dysfunction Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novo Nordisk AS Female Sexual Dysfunction Treatment Product Portfolio
  6. 8.1.5 Novo Nordisk AS Recent Developments
  7. 8.2 Sprout Pharmaceuticals Inc.
  8. 8.2.1 Sprout Pharmaceuticals Inc. Company Information
  9. 8.2.2 Sprout Pharmaceuticals Inc. Business Overview
  10. 8.2.3 Sprout Pharmaceuticals Inc. Female Sexual Dysfunction Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sprout Pharmaceuticals Inc. Female Sexual Dysfunction Treatment Product Portfolio
  12. 8.2.5 Sprout Pharmaceuticals Inc. Recent Developments
  13. 8.3 Emotional Brain BV
  14. 8.3.1 Emotional Brain BV Company Information
  15. 8.3.2 Emotional Brain BV Business Overview
  16. 8.3.3 Emotional Brain BV Female Sexual Dysfunction Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Emotional Brain BV Female Sexual Dysfunction Treatment Product Portfolio
  18. 8.3.5 Emotional Brain BV Recent Developments
  19. 8.4 Duchesnay Inc.
  20. 8.4.1 Duchesnay Inc. Company Information
  21. 8.4.2 Duchesnay Inc. Business Overview
  22. 8.4.3 Duchesnay Inc. Female Sexual Dysfunction Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Duchesnay Inc. Female Sexual Dysfunction Treatment Product Portfolio
  24. 8.4.5 Duchesnay Inc. Recent Developments
  25. 8.5 AMAG Pharmaceuticals Inc.
  26. 8.5.1 AMAG Pharmaceuticals Inc. Company Information
  27. 8.5.2 AMAG Pharmaceuticals Inc. Business Overview
  28. 8.5.3 AMAG Pharmaceuticals Inc. Female Sexual Dysfunction Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AMAG Pharmaceuticals Inc. Female Sexual Dysfunction Treatment Product Portfolio
  30. 8.5.5 AMAG Pharmaceuticals Inc. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst